Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

929 - Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells


11 Sep 2017


Poster display session


Anna Diana


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


A. Diana1, F. Morgillo1, C.M. Della Corte1, C. Di Mauro2, V. Ciaramella1, G. Barra3, V. Belli1, E. Franzese1, R. Bianco2, E. Maiello4, F. De Vita1, F. Ciardiello1, M. Orditura1

Author affiliations

  • 1 Dipartimento Medico-chirurgico Di Internistica Clinica E Sperimentale "f. Magrassi E A. Lanzara", Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT
  • 2 Dipartimento Di Medicina Clinica E Chirurgia, Università degli Studi di Napoli “Federico II”, 80131 - naples/IT
  • 3 Immunologia Clinica, Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT
  • 4 Oncologia, IRCCS Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT


Abstract 929


The phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclitaxel or hormonal therapies in breast cancer. The aim of this study was to evaluate if PI3K or AKT inhibition can prevent resistance to chemotherapy and potentiate its efficacy.


The efficacy of combined treatment of ipatasertib and taselisib plus vinorelbine or paclitaxel or eribulin was evaluated in vitro on human breast cancer cells (with different expression profile of hormonal receptors, HER2, and of PI3Kα mutation) on cell survival by using MTT (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide) and on cell apoptosis by flow-cytometry analysis. We also investigated the effect of combined treatment on downstream intracellular signaling, by western blot analysis, and on metastatic properties, by migration assays. Finally, we analyzed changes in cell cytoskeleton by immunofluorescence.


A significant synergism of ipatasertib or taselib plus anti-microtubule chemotherapy in terms of anti-proliferative, pro-apoptotic and anti-metastatic effect was observed. The combined treatment completely inhibited the activation of proteins downstream of PI3K and MAPK pathways and affected the expression of survivin. Combined treatments completely disorganized the cytoskeleton in human breast cancer cells, thus suggesting a potential mechanism for this combination.


Targeting PI3K may enhance the efficacy of anti-microtubule drugs in human breast cancer.

Clinical trial identification

Legal entity responsible for the study

Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy.


This work has been supported by Associazione Italiana Per La Ricerca Sul Cancro (AIRC)-Project MFAG 2013-N.14392 and drugs were kindly provided by Genentech (Research proposal nr. OR-214726 for taselisib and nr. OR-214797 for ipatasertib).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.